Publication Topic

Rager JE, Suh M, Chappell G, Thompson CM, Proctor DM. 2019. Review of transcriptomic responses to hexavalent chromium exposure in lung cells supports a role of epigenetic mediators in carcinogenesis. Toxicol Lett 305:40-50.

Moffat I, Martinova N, Seidel C, Thompson CM. 2018. Hexavalent chromium in drinking water. Journal AWWA 110:5.

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.

Thompson CM, Young RR, Dinesdurage H, Suh M, Harris MA, Rohr AC, Proctor DM. 2017. Assessment of the mutagenic potential of hexavalent chromium in the duodenum of Big Blue® rats. Toxicol Appl Pharmacol 330(1):48-52.

Rager JE, Ring CL, Fry RC, Suh M, Proctor DM, Haws L, Harris MA, Thompson CM. 2017. High-throughput screening data interpretation in the context of in vivo transcriptomic responses to oral Cr(VI) exposure. Toxicol Sci 158(1):199–212. https://doi.org/10.1093/toxsci/kfx085

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325:9-17.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genetic Toxicol Environ Mutagen 800-801:28-34.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. Environ Molec Mutagen 57:706-716.

De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, Marabotto E, Suh M, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  I. Chemical reduction and mitigation of mutagenicity. Toxicol Appl Pharmacol   306:113-119.

Kirman CR, Suh M, Hays SM, Gürleyük H, Gerads R, De Flora S, Parker W, Lin S, Haws LC, Harris MA, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  II. Ex vivo gastric reduction modeling. Toxicol Appl Pharmacol 306:120-133.